Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Versus Abciximab and SES Versus BMS in AMI
Myocardial Infarction
About this trial
This is an interventional treatment trial for Myocardial Infarction focused on measuring Myocardial infarction, Revascularization, Stent, ST segment elevation
Eligibility Criteria
Inclusion Criteria: ST segment elevation myocardial infarction Schedule for primary percutaneous coronary intervention Informed consent Exclusion Criteria: Administration of fibrinolytic or any GP IIb/IIIa inhibitors for the treatment of current acute myocardial infarction or within 1 month before it History of bleeding diathesis or allergy to the studies drug Major surgery within 30 days Limited life expectancy, e.g. neoplasms, others Pregnancy
Sites / Locations
- Cattedra di Cardiologia, Azienda Ospedaliera Universitaria di Ferrara
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Experimental
Experimental
Experimental
1
2
3
4
Patients will receive abciximab infusion at standard regimen prior undergoing percutaneous coronary intervention for STEMI followed by BMS implantation in the culprit lesion
Abciximab followed by implantation of sirolimus-eluting stent in the culprit lesion
tirofiban infusion followed by bare metal stent implantation
tirofiban and sirolimus-eluting stent